The WHO-World Health Organization welcomed the new coronavirus vaccine developed by two Chinese pharmaceutical companies to be supplied to developing countries through an equitable distribution framework.

The Gavi Vaccine Alliance, an international organization working on vaccination in developing countries, announced on the 12th that it has signed a vaccine purchase contract between Chinese pharmaceutical companies China National Pharmaceutical Group and Sinovac.



The contract states that from July to October, the group will purchase 110 million vaccines in total and promptly supply them to each country through the "COVAX Facility," a framework for fair distribution.



WHO Chief Scientist Swaminasan said at a press conference on the 12th that "many countries are waiting for a vaccine" and welcomed it.



On top of that, Sinovac's vaccine was confirmed to be 90% effective in preventing aggravation as a result of follow-up research, and he acknowledged that he was convinced that the two vaccines were sufficiently effective.



COVAX's plan relies heavily on vaccines manufactured in India, such as AstraZeneca, but the supply has been significantly delayed due to the worsening infection situation in India, and this contract is for developing countries. I would like to accelerate the distribution to India.